Wellington Management Group LLP Trims Stock Position in Qiagen N.V. $QGEN

Wellington Management Group LLP lessened its stake in Qiagen N.V. (NYSE:QGEN) by 13.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,406,763 shares of the company’s stock after selling 1,957,540 shares during the period. Wellington Management Group LLP owned 6.02% of Qiagen worth $484,208,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in QGEN. Boston Partners acquired a new stake in shares of Qiagen during the third quarter worth about $179,450,000. Norges Bank acquired a new stake in shares of Qiagen in the 4th quarter valued at about $166,500,000. Dimensional Fund Advisors LP acquired a new stake in shares of Qiagen in the 3rd quarter valued at about $58,079,000. Price T Rowe Associates Inc. MD grew its stake in Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after buying an additional 906,589 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in Qiagen by 9.7% during the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after buying an additional 697,342 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Down 1.5%

QGEN stock opened at $43.08 on Friday. Qiagen N.V. has a one year low of $32.53 and a one year high of $57.81. The stock has a market capitalization of $8.88 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 4.29 and a beta of 0.63. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The company has a fifty day moving average of $41.37 and a 200-day moving average of $40.66.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The business had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business’s revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, analysts expect that Qiagen N.V. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

QGEN has been the subject of a number of research reports. Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 price objective on shares of Qiagen in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised their target price on shares of Qiagen from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $40.00 target price on shares of Qiagen in a report on Friday, August 7th. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Tuesday, July 14th. Finally, Citigroup reiterated a “neutral” rating and set a $45.00 price target (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $43.93.

Qiagen News Roundup

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: The FDA cleared Qiagen’s QIAstat-Dx BCID GPF Plus AMR Panel, giving the company its first entry into the U.S. bloodstream-infection testing market. The automated test detects 20 bacterial and fungal targets plus 10 genetic antimicrobial-resistance markers and runs on a platform with more than 5,200 placements globally, creating potential for added instrument and consumables revenue. Could Qiagen Stock Win as Its FDA Clearance Opens a New Diagnostics Market?
• Positive Sentiment: Qiagen launched QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic-acid extraction. The product builds on a QIAsymphony installed base of more than 3,300 systems and could support recurring demand for Qiagen’s laboratory consumables and assays. QIAGEN Launches QIAsymphony Connect
• Neutral Sentiment: Zacks Research made small, mixed adjustments to its forecasts. It maintained a “Hold” rating and kept fiscal 2026 EPS at $2.43, while raising fiscal 2028 EPS to $2.91 from $2.88. However, fiscal 2027 EPS was lowered to $2.60 from $2.63, suggesting limited near-term earnings momentum. Qiagen analyst estimates
• Negative Sentiment: A Delaware jury found Parse Biosciences, which Qiagen acquired, willfully infringed three patents exclusively licensed to Scale Biosciences, a 10x Genomics subsidiary. Potential damages, royalties, or other remedies could increase costs and create uncertainty around Parse’s business, although the financial impact was not disclosed. 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.